Figure S2 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts

Bomiao Hu, Marc Wiesehöfer,Fernando J. de Miguel,Zongzhi Liu, Lok-Hei Chan,Jungmin Choi,Mary Ann Melnick, Anna Arnal Estape,Zenta Walther, Dejian Zhao,Francesc Lopez-Giraldez,Anna Wurtz,Guoping Cai, Rong Fan,Scott Gettinger,Andrew Xiao,Qin Yan,Robert Homer,Don X. Nguyen,Katerina Politi

crossref（2024）

引用 0|浏览0

暂无评分

摘要

Drug tolerant residual tumors exhibit variable levels of proliferation and low levels of apoptosis. IHC Quantification and additional IHC results to profile cell proliferation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Figure S2 from ASCL1 Drives Tolerance to Osimertinib in &lt;i&gt;EGFR&lt;/i&gt; Mutant Lung Cancer in Permissive Cellular Contexts

Figure S2 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts